Inferences of carboplatin response-related signature by integrating multiomics data in ovarian serous cystadenocarcinoma.

ABSTRACT: Platinum-based chemotherapy, especially carboplatin, is the primary measure to treat patients with ovarian cancer (OC). However, OC patients still have an adverse prognosis due to emergency of chemotherapy resistance. Ovarian serous cystadenocarcinoma (OSC) is the most common histological subtype of OC. Therefore, identifying the key factors that affect chemotherapy resistance and searching novel treatments had become a top priority. In this study, we analyzed carboplatin response-related mRNA, miRNA, DNA methylation, and alternative splicing (AS) and established a drug-resistant signature for carboplatin in OSC. This drug-resistant signature was obviously higher in resistant group than in non-resistant group and had accuracy predictive performance, which demonstrated that this signature c

SUBMITTER: Yan JQ 

PROVIDER: S-EPMC9189566 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature